CXCR4-gp120-IIIB interactions induce caspase-mediated apoptosis of prostate cancer cells and inhibit tumor growth

Molecular Cancer Therapeutics

Volumn 8, Issue 1, 2009, Pages 178-184

  Singh, Shailesh ^a   Bond, Vincent C ^b   Powell, Michael ^b   Singh, Udai P ^c   Bumpers, Harvey L ^b   Grizzle, William E ^d   Lillard Jr , James W ^a,b  

^a University of Louisville School of Medicine   (United States)

^b MOREHOUSE SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CASPASE; CASPASE 3; CASPASE 9; CD34 ANTIGEN; CD36 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; GLYCOPROTEIN GP 120; HERMES ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD34; ANTIGENS, CD44; APOPTOSIS; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; GLYCOPROTEINS; HIV ENVELOPE PROTEIN GP120; MALE; MICE; MICE, SCID; PROSTATIC NEOPLASMS; RECEPTORS, CXCR4; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58149505569     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0643     Document Type: Article

References (46)

1. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002;62:1832-7.
2. Singh S, Singh UP, Grizzle WE, Lillard JW. CXCL12-4 interactions modulates prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest 2004;84:1666-76.
3. Scala S, Ottaiano A, Ascierto PA, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 2005;11:1835-41.
4. Perissinotto E, Cavalloni G, Leone F, et al. Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res 2005;11:490-7.
5. Spano JP, Andre F, Morat L, et al. Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol 2004;15:613-7.
6. Delilbasi CB, Okura M, Iida S, Kogo M. Investigation of CXCR4 in squamous cell carcinoma of the tongue. Oral Oncol 2004;40:154-7.
7. Arya M, Patel HR, McGurk C, et al. The importance of the CXCL12-4 chemokine ligand-receptor interaction in prostate cancer metastasis. J Exp Ther Oncol 2004;4:291-303.
8. Hart CA, Brown M, Bagley S, Sharrard M, Clarke NW. Invasive characteristics of human prostatic epithelial cells: understanding the metastatic process. Br J Cancer 2005;92:503-12.
9. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 2003;167:1676-86.
10. + cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008;41:331-8.
11. Bredeek UF, Harbour MJ. CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1. Eur J Med Res 2007;12:427-34.
12. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-6.
13. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-7.
14. + T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 1998;395:189-94.
15. Berndt C, Mopps B, Angermuller S, Gierschik P, Krammer PH. CXCR4 and CD4 mediate a rapid CD95-independent cell death in CD4(+) T cells. Proc Natl Acad Sci U S A 1998;95:12556-61.
16. Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer 2000;36:1649-60.
17. Plate KH. From angiogenesis to lymphangiogenesis. Nat Med 2001;7:151-2.
18. Fukuda H, Yamada T, Kamata S, Saitoh H. Anatomic distribution of intraprostatic lymphatics: implications for the lymphatic spread of prostate cancer-a preliminary study. Prostate 2000;44:322-7.
19. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001;7:192-8.
20. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001;7:186-91.
21. Littman DR. Chemokine receptors: keys to AIDS pathogenesis? Cell 1998;93:677-80.
22. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998;281:1312-6.
23. Bowen C, Voeller HJ, Kikly K, Gelmann EP. Synthesis of procaspases-3 and -7 during apoptosis in prostate cancer cells. Cell Death Differ 1999;6:394-401.
24. Stennicke HR, Salvesen GS. Catalytic properties of the caspases. Cell Death Differ 1999;6:1054-9.
25. Kuida K, Haydar TF, Kuan CY, et al. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 1998;94:325-37.
26. Hakem R, Hakem A, Duncan GS, et al. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 1998;94:339-52.
27. Reed JC. Cytochrome c: can't live with it-can't live without it. Cell 1997;91:559-62.
28. Cheng EH, Kirsch DG, Clem RJ, et al. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 1997;278:1966-8.
29. Kessel D, Vicente MGH, Reiners JJ, Jr. Initiation of apoptosis and autophagy by photodynamic therapy. Lasers Surg Med 2006;38:482-8.
30. Liotta LA. Tumor invasion and metastases-role of the extracellular matrix: Rhoads Memorial Award Lecture. Cancer Res 1986;46:1-7.
31. Hynes RO. Cell adhesion: old and new questions. Trends Cell Biol 1999;9:M33-7.
32. Stamenkovic I, Amiot M, Pesando JM, Seed B. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 1989;56:1057-62.
33. Aruffo A, Kolanus W, Bevilacqua M, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Science 1990;250:1132-5.
34. Knudson W, Biswas C, Toole BP. Interactions between human tumor cells and fibroblasts stimulate hyaluronate synthesis. Proc Natl Acad Sci U S A 1984;81:6767-71.
35. Yeo TK, Nagy JA, Yeo KT, Dvorak HF, Toole BP. Increased hyaluronan at sites of attachment to mesentery by CD44-positive mouse ovarian and breast tumor cells. Am J Pathol 1996;148:1733-40.
36. Gunthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65:13-24.
37. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev 2000;14:163-76.
38. Yu Q, Toole BP, Stamenkovic I. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J Exp Med 1997;186:1985-96.
39. Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999;13:35-48.
40. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-9.
41. Bettencourt MC, Bauer JJ, Sesterhenn IA, Connelly RR, Moul JW. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 1998;160:459-65.
42. Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 1994;73:678-87.
43. Barth PJ, Weingartner K, Kohler HH, Bittinger A. Assessment of the vascularization in prostatic carcinoma: a morphometric investigation. Hum Pathol 1996;27:1306-10.
44. Podgrabinska S, Braun P, Velasco P, Kloos B, Pepper MS, Skobe M. Molecular characterization of lymphatic endothelial cells. Proc Natl Acad Sci U S A 2002;99:16069-74.
45. Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 1999;144:789-801.
46. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nat Med 2000;6:1102-3.